Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Iroko’s Zorvolex | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

FDA Approves Iroko’s Zorvolex

Pain treatment uses iCeutica’s SoluMatrix Fine Particle Technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Iroko Pharmaceuticals received approval from the FDA for Zorvolex (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. Zorvolex was approved at dosage strengths that are 20% lower than currently available diclofenac products.
 
The approval was supported by data from a Phase III multi-center, randomized study in which patients treated with Zorvolex reported significant pain relief compared with patients receiving placebo.
 
Iroko developed Zorvolex capsules under a collaboration and license agreement with iCeutica utilizing iCeutica’s SoluMatrix Fine Particle Technology, a platform that uses a dry milling process to make finely dispersed drug particles that are 10 – 200 times smaller than conventional drug particles. The SoluMatrix process has the potential to create drugs that work faster and more effectively at lower doses.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics